Introduction: Dihydroartemisinin (DHA) is a first-line antimalarial drug with relatively low toxicity. DHA has been speculated to possess a broad-spectrum antitumour effect. However, the potential value of DHA for the treatment of endometrial carcinoma or cervical cancer is unclear.
INTRODUCTION
Endometrial carcinoma and cervical cancers are the third and fourth most common causes of cancer-related death in women worldwide, respectively. (1, 2) Because of the widespread use of cervical screening programmes in developed countries, the incidence of cervical cancer has reduced. (1) However, in the past decades, rates of endometrial cancer have risen in a number of countries, likely due to the increasingly ageing populations and growing obesity rates. (2, 3) Even with current advanced treatment strategies, the side effects and drug resistance of chemotherapeutic agents have limited the efficacy of treatment. (3) (4) (5) It is therefore of significant importance to discover novel agents with less severe side effects and lower drug resistance.
Autophagy is a lysosomal pathway involved in the degradation of cytoplasmic macromolecules and organelles. (6, 7) It plays a dual role in cancer development and treatment.
Increased autophagy promotes the generation of metabolic substrates, which maintains cancer homeostasis, and thereby limits chemotherapy cytotoxicity. However, excessive selfdigestion of essential cellular components can be toxic to cancer cells. The microtubuleassociated protein 1 light chain 3 (LC3) system is important for the transport and maturation of the autophagosome. Accordingly, this study aimed to elucidate the role of autophagy in dihydroartemisinin (DHA)-induced cytotoxicity in both cervical and endometrial cancer cells.
Transferrin receptor (TfR) is a serum glycoprotein that transfers iron, a co-factor for DNA synthesis, from the extracellular matrix to the intracellular space. (8, 9) Because of rapid proliferation, the demand for iron in cancer cells is much greater than in normal cells, resulting in elevated TfR expression in cancer cells. (8, 9) Apoptosis can be classified into extrinsic and intrinsic pathways. However, the potential correlation between TfR and the apoptotic pathway is unknown. Additionally, the relationship between apoptosis key factors, including caspase-3, and TfR is still unclear.
DHA, an artemisinin derivative, was originally an effective agent against malaria, with minimal side effects. Later, DHA was reported to have anticancer effects. (10) It has been found that DHA displays antiproliferative effects against various tumour cell lines, including cancers of the lung, breast, colon, pancreas, liver, ovary and prostate, as well as some anticancer drug-resistant cell lines, (8, 11) and that it inhibits cell growth while inducing apoptosis in a dose-and time-dependent manner. (12) However, some limitations constrain its clinical application, such as low bioavailability caused by its poor solubility. (13) The antitumour mechanisms of DHA are still not fully understood. Inhibition of tumour cell growth by DHA may partially be due to the production of reactive oxygen species. (14, 15) DHA may also affect expression and function of adhesion proteins, matrix metalloproteinases and tissue inhibitors to inhibit cancer metastasis. However, the role of DHA in autophagy and the mechanism by which DHA induces autophagy, apoptosis and its association with TfR remain unclear.
Cisplatin is currently the best known chemotherapeutic drug available for the treatment of ovarian cancer. However, for cisplatin-resistant cancer cells, new effective anticancer drugs are urgently needed.
LC3 is a soluble protein that is distributed ubiquitously in mammalian tissues and cultured cells. Upon autophagic stimulation, a cytosolic form of LC3 (LC3-I) is conjugated to phosphatidylethanolamine to form LC3-phosphatidylethanolamine conjugate (LC3-II), which is recruited to isolation membranes to facilitate the generation of autophagosomes.
Autophagosomes then fuse with lysosomes to form autolysosomes, and intra-autophagosomal components are degraded by lysosomal hydrolases. p62 plays a key role in the formation of cytoplasmic proteinaceous inclusion. (16) The p62 protein recognises toxic cellular waste, which is then scavenged by a sequestration process known as self-eating or autophagy. The p62 protein itself is also a substrate of autophagy. Increased autophagic activity results in rapid degradation of p62, whereas a lack of autophagy leads to accumulation of p62. (17) In the present study, we explored the impact of DHA treatment on cell proliferation, apoptosis and autophagy in endometrial and cervical cancer cells. Our results would provide further evidence supporting DHA as a possible anticancer drug for the treatment of endometrial carcinoma and cervical cancer. Data was expressed as mean ± standard deviation (SD) of at least three independent experiments. Data was analysed using Student's t-test when only two groups were present or assessed using one-way analysis of variance when more than two groups were compared.
METHODS
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Differences between groups were considered to be statistically significant at p < 0.05.
RESULTS
Anticancer activity was seen in human endometrial adenocarcinoma cells when they were treated with various concentrations of DHA or cisplatin, either alone or in combination, over a period of 96 hours (Fig. 1) . Cell survival, assayed by MTT assay, was inhibited by DHA in a dose-and time-dependent manner. The half-maximal inhibitory concentrations, when extrapolated from the dose-response curve of Ishikawa cells for DHA alone, were 13.6 M, 30.5 M and 112.7 M, respectively, at 24 hours, 48 hours and 96 hours.
Results of the MTT assay indicated that treatment of Ishikawa cells with DHA at 20 M, 40 M or 80 M for 96 hours exhibited a potent antiproliferative effect (p < 0.01; Fig.   1a ). It also revealed that DHA at 40 M and 80 M inhibited cancer cells for 48 hours and 24 hours, respectively (p < 0.05; Fig. 1a ). Treatment with cisplatin at 2 M, 20 M or 200 M for 96 hours exhibited a potent antiproliferative effect (p < 0.01; Fig. 1b ). However, no such inhibitory action was seen in cells treated with DHA and cisplatin in combination (Fig. 1c ).
The quantitative results of flow cytometry performed to investigate whether reduced cell survival upon treatment with DHA and/or cisplatin of Ishikawa cells was associated with increased apoptosis and necrosis (Fig. 2) showed that the addition of DHA, or a combination of DHA and cisplatin, led to a significant increase in the number of cell apoptosis and/or necrosis at 24 hours after treatment (p < 0.05), indicating that treatment with DHA did induce increased apoptosis and necrosis.
The mRNA levels of caspase-3 and TfR in human endometrial adenocarcinoma cells treated with DHA alone, cisplatin alone or DHA in combination with cisplatin were measured by RT-PCR, with ACTB as a reference gene. We found that TfR mRNA expression was decreased in groups with DHA at 36 hours (p < 0.05; Fig. 3a ). Caspase-3 mRNA expression in cells treated with DHA at 36 hours was significantly increased when compared to control (p < 0.05; Fig. 3a ). Results of RT-PCR suggested that DHA induced apoptosis more potently than cisplatin, possibly with the assistance of TfR.
To further determine whether DHA triggered caspase activation in Ishikawa cells, protein levels of cleaved caspase-3 were examined by ELISA. As shown in Fig. 3b , the addition of cisplatin, DHA or both led to significantly higher levels of cleaved caspase-3 when compared with vehicle-treated control cells (p < 0.05). The levels of cleaved caspase-3 were markedly higher at 24 hours or 12 hours of treatment when compared with the negative control (p < 0.05). Significant difference was not found between cells treated with DHA and cisplatin. However, the highest levels of cleaved caspase-3 for any time point were observed in cells treated with both DHA and cisplatin (p < 0.05). Finally, we examined the effects of DHA on apoptosis and autophagy in HeLa cells.
Ishikawa cells treated with
As shown in Fig. 6a , similar to the observations in human endometrial cancer cells, treatment with various concentrations of DHA for 48 hours resulted in a dose-dependent reduction of cell survival. Addition of DHA also caused the cleavage of caspase-3, suggesting an activation of the apoptosis pathway (Fig. 6b) . Moreover, the effects of DHA on the autophagy pathway in HeLa cells, when examined by Western blotting, demonstrated that the addition of DHA led to increased conversion of LC3-I to LC3-II ( Fig. 6c ) and accelerated degradation of p62 (Fig. 6d) , which is a substrate of autophagy. Together, our results indicated that DHA triggered cell death in human cervical cancer cells by promoting the apoptosis pathway and that DHA treatment also induced autophagy pathways.
DISCUSSION
TfR might be upregulated in order to mediate endocytosis of transferrin loaded with increased concentrations of iron. (17, 18) We found that DHA decreased TfR mRNA expression and this knockdown of TfR further enhanced the cytotoxic activity of DHA. Most cancer cells have greater numbers of iron-attracting TfR on their cell surface when compared to normal cells. (18) Thus, we speculated that knockdown TfR lead to the death of Ishikawa cells due to lack of iron uptake. DHA could possibly interact with the upregulated iron receptor TfR to form free radicals, thereby acting as an effective anticancer drug. (8) Our results indicated that knockdown of TfR may synergistically enhance the anticancer effects of DHA through depletion of iron metabolism in cervical and endometrial carcinoma cells.
DHA was also reported to cause an arrest of cell cycle progression. (19) It was previously shown that DHA treatment resulted in a gradual G1 and G2/M arrest with increased doses of both G1 and G2 peaks, while DHA decreased G0/G1 phase doses in ovarian cell lines (OVCA432 and SKOV3 cells). (20) Meanwhile, cell cycle analysis showed that DHA inhibited cell proliferation by inducing cell cycle arrest at S phase in a concentration-dependent manner (SKOV3/DDP cells). (16) Further studies on cycle analysis are warranted on the many cell cycle genes and proteins, including CDKN1A, CCNE1, CDKN1C, CDKN2D and Cdk1.
The cellular response to DHA treatment may include various cell death pathways (e.g. apoptosis, autophagy and necrosis). (21) Caspase-3 is ubiquitously distributed and is a main effector caspase for the apoptotic cascade within cells. (18) We found that cleaved caspase-3 protein levels in cells treated with DHA alone or in combination with cisplatin were significantly higher than in control cells, and that cleaved caspase-3 increased significantly in a time-dependent manner in Ishikawa cells, indicating an induction of apoptosis with DHA treatment. We found that DHA treatment resulted in increased LC3-II/LC3-I ratio, decreased p62 protein level and elevated numbers of MDC-positive autophagosomes, suggesting enhanced autophagic activity with DHA treatment. Autophagy plays a dual role in cell survival. (22) We showed that inhibition of autophagy further enhanced cell death, suggesting a cytoprotective function for DHA-induced activation of autophagy. By blocking the autophagy pathway using 3-MA and reducing DHA-induced cancer death, we concluded that the DHA effect against tumour cells was mediated through the autophagy pathway.
Our findings that DHA, with or without cisplatin, significantly induced cell death in the Ishikawa cell line suggested that DHA could also be a good candidate for the treatment of cisplatin-resistant endometrial carcinoma. Similar findings were reported for the effects of DHA on cisplatin-resistant ovarian cancer cells (SKOV3/cisplatin). (16) All our results indicated that cisplatin treatment combined with DHA could enhance cisplatin-induced proliferation inhibition or facilitate the killing of cisplatin-resistant cancer cells.
In summary, the present study provides evidence that DHA has a potent antitumour effect against human endometrial cancer cells and cervical cancer cells, likely by facilitating apoptosis as well as reducing the mRNA expression of TfR. We presumed that DHA might cause cell death through the autophagy pathway, which can be influenced by 3-MA. Future studies and further investigation of the possible clinical application of DHA for the treatment of endometrial carcinoma and cervical cancer is warranted. Our results reveal further clues that explain TfR regulation in autophagy and apoptosis induced by DHA. Reactive oxygen species were suggested to be a target of DHA in cancer cell lines and this is an area that warrants further investigation. 
